Characteristics of patients according to the type of MPN
| Characteristic . | ET . | PV . |
|---|---|---|
| No. of patients | 297 | 125 |
| Sex, male/female | 93/204 | 55/70 |
| Age, y* | 59 (13-93) | 62 (19-89) |
| Hb, g/L* | 139 (82-174) | 179 (136-238) |
| WBC, × 109/L* | 8.7 (3.9-24) | 10.7 (5-29) |
| Platelets, × 109/L* | 762 (257-2600) | 590 (129-1300) |
| Abnormal karyotype | 5/196 (3%) | 5/77 (6%) |
| JAK2 mutation | 149/281 (53%) | 103/109 (95%) |
| JAK2 genotype (rs12340895) | ||
| CC | 121 (42%) | 32 (28%) |
| CG | 138 (47%) | 48 (41%) |
| GG | 31 (11%) | 36 (31%) |
| Progression to AML | 35 (12%) | 29 (23%) |
| New nonmyeloid malignancies† | ||
| Skin, nonmelanoma | 8 | 8 |
| Lymphoid | 1 | 7 |
| Breast | 2 | 5 |
| Gastrointestinal tract | 1 | 4 |
| Prostate | 3 | 3 |
| Kidney and urinary tract | 2 | 3 |
| Lung | 3 | 0 |
| Other | 2 | 2 |
| Total | 22 | 32 |
| Follow-up, y* | 8.7 (1-24) | 8.4 (1-37) |
| Died | 47 (16%) | 43 (34%) |
| Characteristic . | ET . | PV . |
|---|---|---|
| No. of patients | 297 | 125 |
| Sex, male/female | 93/204 | 55/70 |
| Age, y* | 59 (13-93) | 62 (19-89) |
| Hb, g/L* | 139 (82-174) | 179 (136-238) |
| WBC, × 109/L* | 8.7 (3.9-24) | 10.7 (5-29) |
| Platelets, × 109/L* | 762 (257-2600) | 590 (129-1300) |
| Abnormal karyotype | 5/196 (3%) | 5/77 (6%) |
| JAK2 mutation | 149/281 (53%) | 103/109 (95%) |
| JAK2 genotype (rs12340895) | ||
| CC | 121 (42%) | 32 (28%) |
| CG | 138 (47%) | 48 (41%) |
| GG | 31 (11%) | 36 (31%) |
| Progression to AML | 35 (12%) | 29 (23%) |
| New nonmyeloid malignancies† | ||
| Skin, nonmelanoma | 8 | 8 |
| Lymphoid | 1 | 7 |
| Breast | 2 | 5 |
| Gastrointestinal tract | 1 | 4 |
| Prostate | 3 | 3 |
| Kidney and urinary tract | 2 | 3 |
| Lung | 3 | 0 |
| Other | 2 | 2 |
| Total | 22 | 32 |
| Follow-up, y* | 8.7 (1-24) | 8.4 (1-37) |
| Died | 47 (16%) | 43 (34%) |